Oncolys Biopharma Inc
TSE:4588
Oncolys Biopharma Inc
Revenue
Oncolys Biopharma Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Revenue
¥63m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
GNI Group Ltd
TSE:2160
|
Revenue
¥26B
|
CAGR 3-Years
39%
|
CAGR 5-Years
39%
|
CAGR 10-Years
64%
|
|
PeptiDream Inc
TSE:4587
|
Revenue
¥28.7B
|
CAGR 3-Years
35%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
TSE:4974
|
Revenue
¥47.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
Revenue
¥2.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
11%
|
S
|
StemRIM Inc
TSE:4599
|
Revenue
¥2.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
See Also
What is Oncolys Biopharma Inc's Revenue?
Revenue
63m
JPY
Based on the financial report for Dec 31, 2023, Oncolys Biopharma Inc's Revenue amounts to 63m JPY.
What is Oncolys Biopharma Inc's Revenue growth rate?
Revenue CAGR 5Y
-18%
Over the last year, the Revenue growth was -94%. The average annual Revenue growth rates for Oncolys Biopharma Inc have been -41% over the past three years , -18% over the past five years .